Innate Pharma (IPHA) Projected to Post Quarterly Earnings on Thursday

Innate Pharma (NASDAQ:IPHA) is anticipated to issue its results before the market opens on Thursday, November 13th. Analysts expect the company to announce earnings of ($0.3285) per share and revenue of $1.96 million for the quarter.

Innate Pharma Stock Performance

NASDAQ:IPHA remained flat at $1.82 during trading hours on Thursday. 1,039 shares of the company were exchanged, compared to its average volume of 82,429. Innate Pharma has a 12-month low of $1.29 and a 12-month high of $3.51. The business has a 50 day moving average of $2.02 and a 200-day moving average of $2.04.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on IPHA shares. BTIG Research reaffirmed a “buy” rating and issued a $8.00 target price on shares of Innate Pharma in a research note on Wednesday, October 29th. Leerink Partnrs lowered shares of Innate Pharma from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 18th. HC Wainwright set a $5.00 price target on shares of Innate Pharma and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Leerink Partners restated a “market perform” rating and issued a $2.00 price objective (down from $10.00) on shares of Innate Pharma in a report on Thursday, September 18th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Innate Pharma in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $5.00.

Innate Pharma Company Profile

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.